Piramal Pharma Ltd. | Large-cap | Healthcare
₹202.83
0.92%
| Piramal Pharma Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 91.5B
Gross Profit 59.2B 64.69%
Operating Income 6.3B 6.87%
Net Income 911.3M 1.00%
EPS (Diluted) ₹0.68

Balance Sheet Metrics

Total Assets 156.8B
Total Liabilities 75.5B
Shareholders Equity 81.3B
Debt to Equity 0.93

Cash Flow Metrics

Operating Cash Flow 2.4B
Free Cash Flow 2.3B

Revenue & Profitability Trend

Piramal Pharma Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 91.5B 81.1B 70.3B 64.7B 29.0B
Cost of Goods Sold 32.3B 32.6B 30.0B 26.8B 12.5B
Gross Profit 59.2B 48.5B 40.3B 37.9B 16.5B
Operating Expenses 21.7B 16.8B 15.2B 13.1B 6.5B
Operating Income 6.3B 4.3B -479.7M 3.7B 4.8B
Pre-tax Income 4.1B 1.8B -1.2B 4.8B 6.9B
Income Tax 3.2B 1.6B 663.1M 1.1B 1.2B
Net Income 911.3M 178.2M -1.9B 3.8B 5.7B
EPS (Diluted) ₹0.68 ₹0.14 -₹1.54 ₹3.09 ₹4.70

Income Statement Trend

Piramal Pharma Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets 58.0B 54.6B 48.4B 40.7B 17.7B
Non-Current Assets 98.8B 98.5B 96.9B 87.3B 39.9B
Total Assets 156.8B 153.1B 145.2B 128.0B 57.6B
Liabilities
Current Liabilities 37.7B 43.7B 38.4B 30.3B 14.7B
Non-Current Liabilities 37.9B 30.3B 39.1B 30.7B 1.8B
Total Liabilities 75.5B 74.0B 77.5B 61.0B 16.6B
Equity
Total Shareholders Equity 81.3B 79.1B 67.7B 67.0B 41.0B

Balance Sheet Composition

Piramal Pharma Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income 3.4B 1.2B -1.6B 4.4B 3.5B
Operating Cash Flow 2.4B -660.5M 1.1B 2.2B 812.5M
Investing Activities
Capital Expenditures -6.6B -7.1B -9.5B -8.6B -551.8M
Investing Cash Flow -5.2B -4.6B -14.1B -18.9B -38.4B
Financing Activities
Dividends Paid -144.7M - -670.0M -500.0M -
Financing Cash Flow 342.5M -16.9B -3.3B -274.4M 41.2B
Free Cash Flow 2.3B 2.9B -4.8B -1.2B -233.9M

Cash Flow Trend

Piramal Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 294.07
Forward P/E 43.22
Price to Book 3.26
Price to Sales 2.89
PEG Ratio 0.75

Profitability Ratios

Profit Margin 1.00%
Operating Margin 11.56%
Return on Equity 1.14%
Return on Assets 2.54%

Financial Health

Current Ratio 1.54
Debt to Equity 59.77
Beta 0.08

Per Share Data

EPS (TTM) ₹0.68
Book Value per Share ₹61.40
Revenue per Share ₹69.29

Financial data is updated regularly. All figures are in the company's reporting currency.